RU2003132054A - Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета - Google Patents
Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета Download PDFInfo
- Publication number
- RU2003132054A RU2003132054A RU2003132054/14A RU2003132054A RU2003132054A RU 2003132054 A RU2003132054 A RU 2003132054A RU 2003132054/14 A RU2003132054/14 A RU 2003132054/14A RU 2003132054 A RU2003132054 A RU 2003132054A RU 2003132054 A RU2003132054 A RU 2003132054A
- Authority
- RU
- Russia
- Prior art keywords
- effective amount
- pharmaceutically effective
- insulin
- prodrugs
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Claims (5)
1. Способ профилактики диабета у животных, включающий в себя введение животным, у которых существует риск развития диабета, фармацевтически эффективного количества агента-сенсибилизатора инсулина и фармацевтически эффективного количества ингибитора FBPазы или его пролекарств или солей.
2. Способ лечения ослабленной толерантности к глюкозе, включающий в себя введение пациентам, в случае необходимости, фармацевтически эффективного количества агента-сенсибилизатора инсулина и фармацевтически эффективного количества ингибитора FBPазы или его пролекарств или солей.
3. Способ лечения резистентности к инсулину, включающий в себя введение пациентам, в случае необходимости, фармацевтически эффективного количества агента-сенсибилизатора инсулина и фармацевтически эффективного количества ингибитора FBPазы или его пролекарств или солей.
4. Способ по пункту 1, отличающийся тем, что указанные животные, у которых существует риск развития диабета, имеют заболевание или состояние, выбранное из группы, состоящей из ослабленной толерантности к глюкозе, резистентности к инсулину, гипергликемии, ожирения, ускоренного глюконеогенеза и повышенного поглощения глюкозы печенью.
5. Способ лечения или профилактики заболевания или состояния, выбранного из группы, состоящей из гиперлипидемии, атеросклероза, ишемического повреждения, гипертензии и гиперхолестеринемии, включающий в себя введение животному, в случае необходимости, фармацевтически эффективного количества агента-сенсибилизатора инсулина и фармацевтически эффективного количества ингибитора FBPазы или его пролекарств или солей.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11471898P | 1998-12-24 | 1998-12-24 | |
| US60/114,718 | 1998-12-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001120726/15A Division RU2227749C2 (ru) | 1998-12-24 | 1999-12-22 | Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003132054A true RU2003132054A (ru) | 2005-04-20 |
Family
ID=22357016
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001120726/15A RU2227749C2 (ru) | 1998-12-24 | 1999-12-22 | Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета |
| RU2003132054/14A RU2003132054A (ru) | 1998-12-24 | 2003-10-31 | Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001120726/15A RU2227749C2 (ru) | 1998-12-24 | 1999-12-22 | Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1143955B1 (ru) |
| JP (1) | JP2003515523A (ru) |
| KR (3) | KR100689943B1 (ru) |
| CN (3) | CN100352505C (ru) |
| AT (1) | ATE300288T1 (ru) |
| AU (1) | AU771039B2 (ru) |
| BR (1) | BR9917005A (ru) |
| CA (1) | CA2354053A1 (ru) |
| CZ (1) | CZ20012353A3 (ru) |
| DE (1) | DE69926400T2 (ru) |
| DK (1) | DK1143955T3 (ru) |
| ES (1) | ES2246586T3 (ru) |
| HK (1) | HK1046863B (ru) |
| HU (1) | HUP0402506A3 (ru) |
| ID (1) | ID30237A (ru) |
| IL (2) | IL143569A0 (ru) |
| MX (1) | MXPA01006511A (ru) |
| NO (1) | NO20013115L (ru) |
| NZ (1) | NZ512219A (ru) |
| PL (1) | PL352756A1 (ru) |
| PT (1) | PT1143955E (ru) |
| RU (2) | RU2227749C2 (ru) |
| SK (1) | SK9172001A3 (ru) |
| WO (1) | WO2000038666A2 (ru) |
| ZA (1) | ZA200105016B (ru) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| BR9913532A (pt) | 1998-09-09 | 2001-10-02 | Metabasis Therapeutics Inc | Novos inibidores heteroaromáticos de frutose 1,6-bifosfatase |
| PL356525A1 (en) * | 1999-12-22 | 2004-06-28 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
| IL151248A0 (en) * | 2000-03-08 | 2003-04-10 | Metabasis Therapeutics Inc | Novel aryl fructose-1,6-bisphosphatase inhibitors |
| CA2412142A1 (en) * | 2000-07-06 | 2002-01-17 | Metabasis Therapeutics, Inc. | A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| AU2002215218A1 (en) * | 2000-11-17 | 2002-05-27 | Takeda Chemical Industries Ltd. | Isoxazole derivatives |
| EP1504014B1 (en) | 2002-05-13 | 2015-12-02 | Metabasis Therapeutics, Inc. | Process for preparation of cyclic prodrugs of pmea and pmpa |
| EP1532157A4 (en) | 2002-05-13 | 2009-02-25 | Metabasis Therapeutics Inc | NEW PRODRUGS FROM PMEA TO PHOSPHONIC ACID BASE AND ITS ANALOG |
| JP4719465B2 (ja) * | 2002-09-04 | 2011-07-06 | ディーエスエム アイピー アセッツ ビー．ブイ． | インスリン感受性増強剤およびペプチド画分を含む栄養補給用および治療用組成物 |
| UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
| EA009919B1 (ru) * | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
| CN1902196B (zh) | 2003-12-26 | 2010-12-29 | 协和发酵麒麟株式会社 | 噻唑衍生物 |
| WO2006023515A2 (en) * | 2004-08-18 | 2006-03-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
| CN101119748A (zh) * | 2004-12-13 | 2008-02-06 | 第一三共株式会社 | 用于治疗糖尿病的药物组合物 |
| EP1825854A1 (en) * | 2004-12-15 | 2007-08-29 | Daiichi Sankyo Company, Limited | MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR |
| EP1889618A4 (en) * | 2005-05-27 | 2010-11-24 | Daiichi Sankyo Co Ltd | COMBINED MEDICINE FOR THE TREATMENT OF DIABETES |
| WO2006137527A1 (ja) | 2005-06-23 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | チアゾール誘導体 |
| EP2089017A2 (en) | 2006-11-02 | 2009-08-19 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| US9631825B2 (en) | 2012-12-18 | 2017-04-25 | Nortek Air Solutions, Llc | Air filter assembly |
| JP2017512183A (ja) | 2014-02-13 | 2017-05-18 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
| EP3164136A4 (en) | 2014-07-02 | 2018-04-04 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
| CN105481896A (zh) * | 2015-12-03 | 2016-04-13 | 浙江大学 | 一种地马格列的制备方法 |
| CN113416739B (zh) * | 2021-06-24 | 2022-04-19 | 黑龙江八一农垦大学 | 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968790A (en) * | 1988-08-12 | 1990-11-06 | American Cyanamid Company | Antidiabetic phosphates |
| JPH03157377A (ja) * | 1988-11-18 | 1991-07-05 | Takeda Chem Ind Ltd | チオ尿素誘導体及びａｇｅ生成阻害剤 |
| CA2008325A1 (en) * | 1989-01-24 | 1990-07-24 | Harry E. Gruber | Method and compounds for aica riboside delivery and for lowering blood glucose |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| WO1998039342A1 (en) * | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| AU6452098A (en) * | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| JP2001515482A (ja) * | 1997-03-07 | 2001-09-18 | メタバシス・セラピューティクス・インコーポレイテッド | フルクトース−１，６−ビスホスファターゼの新規なベンズイミダゾールインヒビター |
-
1999
- 1999-12-22 RU RU2001120726/15A patent/RU2227749C2/ru not_active IP Right Cessation
- 1999-12-22 DE DE69926400T patent/DE69926400T2/de not_active Expired - Lifetime
- 1999-12-22 WO PCT/US1999/030713 patent/WO2000038666A2/en active Application Filing
- 1999-12-22 ID IDW00200101612A patent/ID30237A/id unknown
- 1999-12-22 HU HU0402506A patent/HUP0402506A3/hu active IP Right Revival
- 1999-12-22 JP JP2000590620A patent/JP2003515523A/ja active Pending
- 1999-12-22 AT AT99964313T patent/ATE300288T1/de active
- 1999-12-22 CN CNB998163562A patent/CN100352505C/zh not_active Expired - Fee Related
- 1999-12-22 CN CNA2005100806150A patent/CN1714866A/zh active Pending
- 1999-12-22 KR KR1020017008102A patent/KR100689943B1/ko not_active IP Right Cessation
- 1999-12-22 IL IL14356999A patent/IL143569A0/xx active IP Right Grant
- 1999-12-22 AU AU20583/00A patent/AU771039B2/en not_active Ceased
- 1999-12-22 SK SK917-2001A patent/SK9172001A3/sk unknown
- 1999-12-22 KR KR1020067022095A patent/KR20060114724A/ko not_active Application Discontinuation
- 1999-12-22 DK DK99964313T patent/DK1143955T3/da active
- 1999-12-22 ES ES99964313T patent/ES2246586T3/es not_active Expired - Lifetime
- 1999-12-22 CA CA002354053A patent/CA2354053A1/en not_active Abandoned
- 1999-12-22 BR BR9917005-1A patent/BR9917005A/pt not_active Application Discontinuation
- 1999-12-22 KR KR1020077008649A patent/KR20070046210A/ko not_active Application Discontinuation
- 1999-12-22 EP EP99964313A patent/EP1143955B1/en not_active Expired - Lifetime
- 1999-12-22 PL PL99352756A patent/PL352756A1/xx not_active Application Discontinuation
- 1999-12-22 CZ CZ20012353A patent/CZ20012353A3/cs unknown
- 1999-12-22 PT PT99964313T patent/PT1143955E/pt unknown
- 1999-12-22 NZ NZ512219A patent/NZ512219A/xx not_active IP Right Cessation
- 1999-12-22 CN CNA2007101628889A patent/CN101164618A/zh active Pending
- 1999-12-22 MX MXPA01006511A patent/MXPA01006511A/es active IP Right Grant
-
2001
- 2001-06-05 IL IL143569A patent/IL143569A/en not_active IP Right Cessation
- 2001-06-19 ZA ZA200105016A patent/ZA200105016B/en unknown
- 2001-06-21 NO NO20013115A patent/NO20013115L/no not_active Application Discontinuation
-
2002
- 2002-11-22 HK HK02108475.5A patent/HK1046863B/zh not_active IP Right Cessation
-
2003
- 2003-10-31 RU RU2003132054/14A patent/RU2003132054A/ru not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003132054A (ru) | Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета | |
| LU91926I2 (fr) | Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®) | |
| CN102481276A (zh) | 基于化学感受受体配体的治疗法 | |
| DE60022333D1 (de) | Natrium kanalblocker zusammensetzungen und deren verwendung | |
| BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
| ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
| BRPI0407757A (pt) | derivados de benzamida tetracìclica e métodos de uso dos mesmos | |
| BR0314760A (pt) | Compostos orgânicos | |
| BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
| BR0300301A (pt) | Método para afetar comportamentos durante o sono e relacionados ao sono | |
| ATE525090T1 (de) | Zusammensetzungen, verfahren und sets zur linderung von gastrointestinalen nebenwirkungen von lipase-hemmern | |
| HK1058190A1 (en) | Novel heterocyclic analogs of diphenylethylene compounds | |
| BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
| BRPI0416591A (pt) | métodos e reagentes para o tratamento de distúrbios inflamatórios | |
| BR9809673A (pt) | Derivados de triptolida úteis no tratamento de doenças autoimunes | |
| PT854724E (pt) | Metodo de tratar a doenca navicular em cavalos | |
| SE9003887L (sv) | Cellproliferationsmatris och anvaendning daerav | |
| KR940021064A (ko) | 프레그네인 유도체의 사용 방법 | |
| KR950032171A (ko) | 옥소피리디닐퀴녹살린 유도체 | |
| US20020128235A1 (en) | Prevention and/or treatment of diabetes mellitus by pharmacologically inhibiting pancreatic beta-cell O-linked protein glycosylation and/or pancreatic beta-cell p135 O-glycosylation | |
| BR9814867A (pt) | Método para tratar discinesias relacionadas a doenças ou induzidas por drogas | |
| AU2018376904A1 (en) | FXR agonists for the treatment of liver diseases | |
| BRPI0414812A (pt) | método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres | |
| BR9810186A (pt) | Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade | |
| CA2493883A1 (en) | Drugs for improving the prognosis of brain injury and a method of screening the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20091205 |